Vascular interventional robotics in China has transitioned from a single NMPA-approved PCI system (R-ONE, the MicroPort–Robocath joint venture product cleared in December 2023) to a competitive field spanning coronary, peripheral, and neurovascular procedures. Domestic entrants — Hanglok-Tech (MULLER), Aopeng (ALLVAS), Jieruo, Zhongke Hongtai, Magbot, Magic Catheter, ETcath, and others — have combined the regulatory opening with the market exit of Siemens Healthineers from coronary intervention robotics, creating clear space for Chinese systems.
The segment covers three distinct clinical applications. Percutaneous coronary intervention (PCI) robots such as R-ONE, MULLER, and emerging domestic systems address procedural precision, stent positioning accuracy, and operator radiation exposure — the latter a notable clinical and staffing concern. Pan-vascular/endovascular platforms like ALLVAS and Hanglok-Tech’s MULLER extend the same remote-manipulation principle to peripheral arterial work, biliary/oncology interventions, and in some systems bronchoscopy. Cardiac electrophysiology robotics — Stereotaxis Genesis and the Titian system — address complex ablation procedures through magnetic or mechanical catheter navigation.
Market structure in PCI robotics is shaped by hospital tender cycles (the 2024 Shanghai public hospital procurement of R-ONE across five flagship centers was a bellwether), reimbursement uncertainty around novel interventional pricing, and device class considerations (most systems target NMPA Class III). Capital deployment and 5G-enabled remote surgery pilots — increasingly visible in cardiac interventional and stroke thrombectomy — will shape adoption over the next two to three years.
See data methodology for how this listing is maintained.